What Happened?
Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 6.9% in the afternoon session after positive trial results from peers Moderna and Merck for their personalized cancer vaccine boosted sentiment across the vaccine sector.
Moderna and Merck announced positive results from a large, late-stage trial of their personalized cancer vaccine for melanoma, according to a joint company press release. The publication revealed the companies’ vaccine reduced the recurrence of the skin cancer in the trial. The news sparked a rally among other vaccine developers.
Is now the time to buy Novavax? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Novavax’s shares are extremely volatile and have had 41 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was 6 months ago when the stock gained 24.4% on the news that the company reported fourth-quarter financial results that significantly beat analyst expectations.
Novavax announced revenue of $147.1 million, up approximately 67% from the prior year’s quarter and well ahead of forecasts. The company also posted a surprise profit with earnings per share (EPS) of $0.11. This was a significant beat, as analysts had expected a loss of $0.49 per share, and it marked a notable turnaround from a loss of $0.51 per share in the same period of the previous year. The strong top-line growth and unexpected profitability drove investor optimism.
Novavax is up 22.7% since the beginning of the year, but at $8.75 per share, it is still trading 21.8% below its 52-week high of $11.19 from February 2026. Despite the year-to-date gain, investors who bought $1,000 worth of Novavax’s shares 5 years ago would now be looking at only $40.21.
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.
Source link
